• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    ACADIA Pharmaceuticals Inc. - Common Stock (NQ:ACAD)

    21.01 -0.26 (-1.22%)
    Streaming Delayed Price Updated: 11:39 AM EDT, Mar 13, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about ACADIA Pharmaceuticals Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9 Next >
    News headline image
    Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operating Overview
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in the European Union
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals to Participate in Citi’s 2025 Global Healthcare Conference
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operating Overview
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Halper Sadeh LLC Encourages Acadia Pharmaceuticals Inc. Shareholders to Contact the Firm to Discuss Their Rights
    From Halper Sadeh LLC
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals to Announce Third Quarter 2025 Financial Results on November 5, 2025
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals Presents Clinical Data from Across Multiple Therapeutic Programs at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals Announces Phase 3 COMPASS PWS Trial of Intranasal Carbetocin (ACP-101) for Hyperphagia in Prader-Willi Syndrome Did Not Meet Primary Endpoint
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Real World Data from LOTUS Study Evaluating Long-term Efficacy and Tolerability Outcomes of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Developmental Medicine and Child Neurology
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals Appoints Konstantina Katcheves as Senior Vice President, Chief Business and Strategy Officer
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operating Overview
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals Appoints Scott Cenci as Chief Information and Data Officer
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2025
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals Hosts Inaugural R&D Day Showcasing Pipeline and Long-Term Value Drivers
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    U.S. Court of Appeals for the Federal Circuit Affirms Prior Delaware District Court Rulings in Favor of Acadia in NUPLAZID® (pimavanserin) Composition of Matter Patent
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.